10

Brain Proteomics

Saime Sürmen and Mustafa Gani Sürmen

University of Health Sciences, İstanbul, Türkiye

With the development of high-resolution mass spectrometry systems, pro-

teomic research has reached a much more advanced level. Next-generation

MS-based proteomic approaches have enabled the robust and large-scale iden-

tification and quantification of biological macromolecules such as proteins.

Defining a biological condition through thousands of proteins is promising in

terms of taking current evaluations of diseases much further. Another impor-

tant aspect in performing these MS-based studies is the advanced algorithms

that enable the processing of tens of gigabytes of raw data obtained from

analyzes and the bioinformatics programs that use them. Thus, proteomics

has paved the way for studies to reconsider many chronic diseases that neg-

atively affect human life. Proteomics offers a powerful molecular perspective,

especially in generating new data on the early diagnosis and characteriza-

tion of chronic diseases such as Alzheimer’s disease (AD), Parkinson’s disease

(PD), and schizophrenia, and thus obtaining more comprehensive diagnosis

and treatment approaches.

10.1

Introduction

Over the past decade, mass spectrometry-based approaches have enabled great

advancements in identification and quantification of thousands of proteins. On

the other hand, new informatics tools continue to be developed that make it

easier for researchers to interpret and present increasingly complex data sets.

Therefore, MS-based proteomics hold promises as powerful approaches to bet-

ter understand various neurodegenerative diseases such as Alzheimer’s disease

(AD), Parkinson’s disease (PD), and schizophrenia [1–3]. In this chapter, MS-

based proteomic studies on common neurological diseases will be discussed to

provide an overview of the field of brain proteomics . The majority of MS-based

DOI: 10.1201/9781003461906-10

250